Background/Aims: The association between hidradenitis suppurativa (HS) and multiple comorbidities has been widely investigated but data about the coexistence of Down syndrome (DS) are scarce. We sought to evaluate the prevalence of DS among a population of HS patients and assess their clinical features. Methods: We collected demographic and clinical data of patients affected with HS referred to three Italian outpatient dermatology clinics. Results: A total of 257 HS patients were enrolled, 62% females and 38% males (mean age [±SD]: 23.3 ± 10.7 years); 9 of the 257 patients (3.5%), 7 females and 2 males, had concomitant HS and DS. The patients with DS and HS had a significantly earlier age of onset (mean age: 14.3 ± 3.6 vs. 23.4 ± 12.31 years; p = 0.029), a significantly younger age at diagnosis (mean age: 21.1 ± 11.1 vs. 31.8 ± 13.5 years; p = 0.015), and were significantly younger (mean age: 23.3 ± 10.7 vs. 34.6 ± 13.07 years; p = 0.005). No significant differences about other clinical data were found between the two groups. Conclusion: The prevalence of DS in HS patients corresponds to a not negligible 3.5% of cases, who experienced an onset of HS at a younger age compared to patients with HS only.

1.
Garg A, Strunk A, Midura M, Papagermanos V, Pomerantz H: Prevalence of hidradenitis suppurativa among patients with Down syndrome: a population based cross-sectional analysis. Br J Dermatol 2017, DOI: 10.1111/bjd.15770.
2.
Hunger RE, Laffitte E, Läuchli S, Mainetti C, Mühlstädt M, Shiller P, Lapointe AK, Meschberger P, Navarini AA: Swiss practice recommendations for the management of hidradenitis suppurativa/acne inversa. Dermatology 2017; 233: 113–119.
3.
Garg A, Kirby JS, Lavian J, Lin G, Strunk A: Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol 2017; 153: 760–764.
4.
Santos JV, Lisboa C, Lanna C, Costa-Pereira A, Freitas A: Is the prevalence of hidradenitis suppurativa being overestimated in Europe? Or is the disease underdiagnosed? Evidence from a nationwide study across Portuguese public hospitals. Int J Dermatol 2017; 56: 1491–1492.
5.
Collier F, Smith RC, Morton CA: Diagnosis and management of hidradenitis suppurativa. BMJ 2013; 346:f2121.
6.
Porter ML, Kimball AB: Comorbidities of hidradenitis suppurativa. Semin Cutan Med Surg 2017; 36: 55–57.
7.
Principi M, Cassano N, Contaldo A, Iannone A, Losurdo G, Barone M, Mastrolonardo M, Vena GA, Ierardi E, Di Leo A: Hidradenitis suppurativa and inflammatory bowel disease: An unusual, but existing association. World J Gastroenterol 2016; 22: 4802–4811.
8.
Dauden E, Lazaro P, Aguilar MD, Blasco AJ, Suarez C, Marin I, Queiro R, Bassas-Vila J, Martorell A, García-Campayo J: Recommendations for the management of comorbidity in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2018; 32: 129–144.
9.
Gasparic J, Theut Riis P, Jemec GB: Recognizing syndromic hidradenitis suppurativa: a review of the literature. J Eur Acad Dermatol Venereol 2017; 31: 1809–1816.
10.
Hamadah I, Haider M, Chisti M, Binamer Y: Hidradenitis suppurativa in Down syndrome: a case series. Pediatr Dermatol 2017; 34: 461–464.
11.
Blok J, Jonkman M, Horváth B: The possible association of hidradenitis suppurativa and Down syndrome: is increased amyloid precursor protein expression resulting in impaired Notch signalling the missing link? Br J Dermatol 2014; 170: 1375–1377.
12.
Denny G, Anadkat MJ: Hidradenitis suppurativa (HS) and Down syndrome (DS): increased prevalence and a younger age of hidradenitis symptom onset. J Am Acad Dermatol 2016; 75: 632–634.
13.
Presson AP, Partyka G, Jensen KM, Devine OJ, Rasmussen SA, McCabe, LL, McCabe ER: Current estimate of Down syndrome population prevalence in the United States. J Pediatr 2013; 163: 1163–1168.
14.
Kiely C, Malik M, Nasir S, Ralph N, Tobin A-M, Watson R: A case series of hidradenitis suppurativa in patients with Down syndrome. Br J Dermatol 2011; 165: 33–34.
15.
Toodayan N: Hidradenitis suppurativa in Down’s syndrome: a case report. Our Dermatology Online 2015; 6: 328–330.
16.
Madan V, Williams J, Lear JT: Dermatological manifestations of Down’s syndrome. Clin Exp Dermatol 2006; 31: 623–629.
17.
Berezovska O, Jack C, Deng A, Gastineau N, Rebeck GW, Hyman BT: Notch1 and amyloid precursor protein are competitive substrates for presenilin1-dependent γ-secretase cleavage. J Biol Chem 2001; 276: 30018–30023.
18.
Melnik BC, Plewig G: Impaired Notch-MKP-1 signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from translational biology. Exp Dermatol 2013; 22: 172–177.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.